Details of the Drug
General Information of Drug (ID: DMXAQZ0)
Drug Name |
2-(4-bromo-2-tert-butylphenoxy)acetic acid
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-[4-BROMO-2-(TERT-BUTYL)PHENOXY]ACETIC ACID; 425372-86-7; 2-(4-bromo-2-tert-butylphenoxy)acetic acid; (4-bromo-2-tert-butylphenoxy)acetic acid; CHEMBL386348; 2-(4-bromo-2-(tert-butyl)phenoxy)acetic acid; 2-[2-(tert-butyl)-4-bromophenoxy]acetic acid; CBMicro_046462; AC1LEXUE; Oprea1_645612; Oprea1_576852; ARONIS011292; SCHEMBL12478128; CTK7J5471; BBB/316; MolPort-000-651-933; GCBNGPDJYUPSBS-UHFFFAOYSA-N; ZINC120478; KS-000042GS; ZX-AS003555; ZX-AL002245; SBB043460; STK948100; BDBM50200269; 3158AE; AKOS000273807; MCULE-9342897788
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 287.15 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||